Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALK1 Follow On Clustering Antibody
- Development stage
- Preclinical
- Lead developer
- Diagonal Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intraperitoneal
01
Overview
ALK1 (also known as ALK1 Follow On Clustering Antibody) is a preclinical-stage clustering antibody agonist being developed by Diagonal Therapeutics for the treatment of cardiovascular diseases. Discovered using the company's proprietary DIAGONAL Product Engine, the therapeutic is designed to restore or enhance ALK1 signaling through antibody-mediated receptor clustering. This mechanism of action aims to correct dysregulated vascular signaling pathways that underlie various cardiovascular disorders.
- Other names
- ALK1ALK-1ALK 1ALK1 Follow-On Clustering AntibodyALK-1 Follow-On Clustering AntibodyALK 1 Follow-On Clustering Antibody
02
Targets
ACVRL1 (Activin receptor-like kinase 1)ACVR2A (Activin receptor type 2A)ACVR2B (Activin receptor type IIB)BMPR2 (Bone morphogenetic protein receptor type II)
Beyond the preview
Go deeper on ALK1 Follow On Clustering Antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALK1 Follow On Clustering Antibody.